SEC Form 4 · accession 0000899243-19-004861
Aimmune Therapeutics, Inc. · AIMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jayson Donald Alexander Dallas
Officer — President and CEO · Director
Period of report
Feb 22, 2019
Accepted (ET)
Feb 26, 2019 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF1,F2 | Feb 22, 2019 | A | 35,000 | $0.00 | A | 98,650 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $23.72 | Feb 22, 2019 | A | 210,000 | A | — | Feb 22, 2029 | Common Stock | 210,000 | 210,000 | D |
Explanation of responses
- F1These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
- F2Includes 60,000 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from June 19, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
- F3The shares subject to the option will vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 22, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.